Your browser doesn't support javascript.
loading
The Effects of Acute Δ9-Tetrahydrocannabinol on Striatal Glutamatergic Function: A Proton Magnetic Resonance Spectroscopy Study.
Bloomfield, Michael A P; Petrilli, Katherine; Lees, Rachel; Hindocha, Chandni; Beck, Katherine; Turner, Ryan J; Onwordi, Ellis Chika; Rane, Neil; Lythgoe, David J; Stone, James M; Curran, H Valerie; Howes, Oliver D; Freeman, Tom P.
Afiliación
  • Bloomfield MAP; Translational Psychiatry Research Group, Research Department of Mental Health Neuroscience, Division of Psychiatry, Institute of Mental Health, Faculty of Brain Sciences, University College London, London, United Kingdom; Clinical Psychopharmacology Unit, Research Department of Clinical, Educational
  • Petrilli K; Translational Psychiatry Research Group, Research Department of Mental Health Neuroscience, Division of Psychiatry, Institute of Mental Health, Faculty of Brain Sciences, University College London, London, United Kingdom; Clinical Psychopharmacology Unit, Research Department of Clinical, Educational
  • Lees R; Translational Psychiatry Research Group, Research Department of Mental Health Neuroscience, Division of Psychiatry, Institute of Mental Health, Faculty of Brain Sciences, University College London, London, United Kingdom; Clinical Psychopharmacology Unit, Research Department of Clinical, Educational
  • Hindocha C; Translational Psychiatry Research Group, Research Department of Mental Health Neuroscience, Division of Psychiatry, Institute of Mental Health, Faculty of Brain Sciences, University College London, London, United Kingdom; Clinical Psychopharmacology Unit, Research Department of Clinical, Educational
  • Beck K; Psychiatric Imaging Group, Medical Research Council London Institute of Medical Sciences, London, United Kingdom; Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom.
  • Turner RJ; Translational Psychiatry Research Group, Research Department of Mental Health Neuroscience, Division of Psychiatry, Institute of Mental Health, Faculty of Brain Sciences, University College London, London, United Kingdom.
  • Onwordi EC; Psychiatric Imaging Group, Medical Research Council London Institute of Medical Sciences, London, United Kingdom; Institute of Clinical Sciences, Faculty of Medicine, Imperial College London, London, United Kingdom; Institute of Psychiatry, Psychology & Neuroscience, King's College London, Londo
  • Rane N; Department of Neuroradiology, Imperial College London Hospitals NHS Trust, London, United Kingdom.
  • Lythgoe DJ; Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom.
  • Stone JM; Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom; South London and Maudsley NHS Foundation Trust, London, United Kingdom.
  • Curran HV; Clinical Psychopharmacology Unit, Research Department of Clinical, Educational & Health Psychology, Division of Psychology, Faculty of Brain Sciences, University College London, London, United Kingdom; National Institute for Health Research University College London Hospitals Biomedical Research
  • Howes OD; Psychiatric Imaging Group, Medical Research Council London Institute of Medical Sciences, London, United Kingdom; Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom; South London and Maudsley NHS Foundation Trust, London, United Kingdom.
  • Freeman TP; Translational Psychiatry Research Group, Research Department of Mental Health Neuroscience, Division of Psychiatry, Institute of Mental Health, Faculty of Brain Sciences, University College London, London, United Kingdom; Clinical Psychopharmacology Unit, Research Department of Clinical, Educational
Article en En | MEDLINE | ID: mdl-34099186
BACKGROUND: Cannabis and its main psychoactive component, Δ9-tetrahydrocannabinol (THC), can elicit transient psychotic symptoms. A key candidate biological mechanism of how THC induces psychotic symptoms is the modulation of glutamate in the brain. We sought to investigate the effects of acute THC administration on striatal glutamate levels and its relationship to the induction of psychotic symptoms. METHODS: We used proton magnetic resonance spectroscopy to measure glutamate levels in the striatum in 20 healthy participants after THC (15 mg, oral) and matched placebo administration in a randomized, double-blind, placebo-controlled design. Psychotic symptoms were measured using the Psychotomimetic States Inventory. RESULTS: We found that THC administration did not significantly change glutamate (glutamate plus glutamine relative to creatine) concentration in the striatum (p = .58; scaled Jeffreys-Zellner-Siow Bayes factor = 4.29). THC increased psychotic symptoms, but the severity of these symptoms was not correlated with striatal glutamate levels. CONCLUSIONS: These findings suggest that oral administration of 15 mg of THC does not result in altered striatal glutamate levels. Further work is needed to clarify the effects of THC on striatal glutamate.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Dronabinol / Alucinógenos Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Humans Idioma: En Revista: Biol Psychiatry Cogn Neurosci Neuroimaging Año: 2021 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Dronabinol / Alucinógenos Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Humans Idioma: En Revista: Biol Psychiatry Cogn Neurosci Neuroimaging Año: 2021 Tipo del documento: Article Pais de publicación: Estados Unidos